Compare abrdn Income Credit Strategies Fund (ACP) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
abrdn Income Credit Strategies Fund vs ResMed Inc. — how do they compare? abrdn Income Credit Strategies Fund trades at $5.1 (market cap $641.16M), while ResMed Inc. trades at $225 (market cap $32.61B). The key difference: ResMed Inc. is far larger — about 50.9× abrdn Income Credit Strategies Fund's market cap, and abrdn Income Credit Strategies Fund pays the higher dividend (18.2%). Which is the better fit depends on your goals.
| ACP | RMD | |
|---|---|---|
Market Cap | $641.16M | $32.61B |
Sector | Financials | Health |
52-Week High | $5.98 | $293.73 |
52-Week Low | $5.01 | $182.82 |
Dividend Yield | 18.2% | 1.17% |
Enterprise Value | — | $31.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACP trades at $5.15 with a 1.38% daily gain, showing neutral technical signals with bearish moving averages. The stock maintains strong profitability with a 95.31% net income margin and attractive valuation at 7.74 P/E ratio. Recent dividend declarations of $0.08 per share demonstrate income focus, though revenue declined from $79M in 2024 to $42M in 2025 before projected recovery to $85M in 2026.
ACP presents a mixed outlook with sustainable dividends and undervalued metrics offset by revenue volatility and high leverage concerns. The 17% distribution rate faces sustainability questions with only 49% supported by net investment income. Investors should weigh the attractive yield against credit spread risks and global exposure in this high-beta closed-end fund.
ResMed (RMD) trades at $226.00, up 2.7% with strong technical momentum and bullish moving averages. The company delivered three consecutive quarterly EPS beats, with Q4 2026 revenue growing 9% to $1.5 billion and non-GAAP EPS rising 16% to $2.95. Fundamentals show robust profitability with 26.94% net margin and 24.27% ROE, though weak 2027 revenue guidance has tempered sentiment.
Outlook remains positive with analyst consensus target of $235 offering 4% upside, but risks include ventilator sales suspension and cost pressures. The stock's current valuation at 21.56 P/E appears reasonable given strong cash flow generation and consistent dividend payments, making it attractive for growth-oriented healthcare investors despite near-term guidance concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.
Read more on ACP →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
